Human papillomavirus is not an etiologic agent of urothelial inverted papillomas

American Journal of Surgical Pathology

Volumn 37, Issue 8, 2013, Pages 1223-1228

  Alexander, Riley E ^a   Davidson, Darrell D ^c   Lopez Beltran, Antonio ^c   Montironi, Rodolfo ^d   Maclennan, Gregory T ^b   Compérat, Eva ^e   Idrees, Muhammad T ^a   Emerson, Robert E ^a   Cheng, Liang ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CÓRDOBA   (Spain)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

carcinogenesis; differential diagnosis; human papillomavirus (HPV) infection; inverted papilloma; p16; urinary bladder

Indexed keywords

P16 PROTEIN, HUMAN; TUMOR PROTEIN; VIRUS ANTIGEN; VIRUS DNA;

ADULT; AGED; ARTICLE; BIOPSY; BLADDER TUMOR; CHEMISTRY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INVERTED PAPILLOMA; ISOLATION AND PURIFICATION; MALE; METABOLISM; MIDDLE AGED; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PATHOGENICITY; PATHOLOGY; PREDICTIVE VALUE; RISK FACTOR; UROTHELIUM; VIROLOGY;

ADULT; AGED; ANTIGENS, VIRAL; BIOPSY; DNA, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PAPILLOMA, INVERTED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84880572796     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3182863fc1     Document Type: Article

References (57)

1. Potts IF, Hirst E. Inverted papilloma of the bladder. J Urol. 1963;90:175-179
2. Cheng L, Lopez-Beltran A, Bostwick DG. Bladder Pathology. Hoboken, NJ: Wiley-Blackwell; 2012
3. Altaffer LF 3rd, Wilkerson SY, Jordan GH, et al. Malignant inverted papilloma and carcinoma in situ of the bladder. J Urol. 1982;128:816-818
4. Cheon J, Kim HK, Kim JJ, et al. Malignant inverted papilloma of the urinary bladder: The histopathological aspect of malignant potential of inverted papilloma. J Korean Med Sci. 1995;10:103-110
5. Grainger R, Gikas PW, Grossman HB. Urothelial carcinoma occurring within an inverted papilloma of the ureter. J Urol. 1990;143:802-804
6. Lazarevic B, Garret R. Inverted papilloma and papillary transitional cell carcinoma of urinary bladder: Report of four cases of inverted papilloma, one showing papillary malignant transformation and review of the literature. Cancer. 1978;42:1904-1911
7. Palvio DH. Inverted papillomas of the urinary tract. A case of multiple, recurring inverted papillomas of the renal pelvis, ureter and bladder associated with malignant change. Scand J Urol Nephrol. 1985;19:299-302
8. Risio M, Coverlizza S, Lasaponara F, et al. Inverted urothelial papilloma: A lesion with malignant potential. Eur Urol. 1988;14: 333-338
9. Gofrit ON, Shapiro A, Pode D, et al. Subepithelial growth patterns in urothelial carcinoma-frequency and prognostic significance. Urol Oncol. 2012;30:49-54
10. Eiber M, van Oers JM, Zwarthoff EC, et al. Low frequency of molecular changes and tumor recurrence in inverted papillomas of the urinary tract. Am J Surg Pathol. 2007;31:938-946
11. Jones TD, Zhang S, Lopez-Beltran A, et al. Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis. Am J Surg Pathol. 2007;31: 1861-1867
12. Lott S, Wang M, Zhang S, et al. FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: Incidence and etiological considerations. Mod Pathol. 2009;22:627-632
13. Sung MT, Eble JN, Wang M, et al. Inverted papilloma of the urinary bladder: A molecular genetic appraisal. Mod Pathol. 2006;19:1289-1294
14. Sung MT, Maclennan GT, Lopez-Beltran A, et al. Natural history of urothelial inverted papilloma. Cancer. 2006;107:2622-2627
15. Hodges KB, Lopez-Beltran A, Maclennan GT, et al. Urothelial lesions with inverted growth patterns: Histogenesis, molecular genetic findings, differential diagnosis and clinical management. BJU Int. 2011;107:532-537
16. Montironi R, Cheng L, Lopez-Beltran A, et al. Inverted (endophytic) noninvasive lesions and neoplasms of the urothelium: The Cinderella group has yet to be fully exploited. Eur Urol. 2011;59:225-230
17. Boucher NR, Anderson JB. Human papillomavirus and bladder cancer. Int Urogynecol J Pelvic Floor Dysfunct. 1997;8:354-357
18. Boucher NR, Scholefield JH, Anderson JB. The aetiological significance of human papillomavirus in bladder cancer. Br J Urol. 1996;78:866-869
19. Cai T, Mazzoli S, Meacci F, et al. Human papillomavirus and nonmuscle invasive urothelial bladder cancer: Potential relationship from a pilot study. Oncol Rep. 2011;25:485-489
20. Lopez-Beltran A, Escudero AL. Human papillomavirus and bladder cancer. Biomed Pharmacother. 1997;51:252-257
21. Shigehara K, Sasagawa T, Kawaguchi S, et al. Etiologic role of human papillomavirus infection in bladder carcinoma. Cancer. 2011;117:2067-2076
22. Youshya S, Purdie K, Breuer J, et al. Does human papillomavirus play a role in the development of bladder transitional cell carcinoma? A comparison of PCR and immunohistochemical analysis. J Clin Pathol. 2005;58:207-210
23. Chan KW, Wong KY, Srivastava G. Prevalence of six types of human papillomavirus in inverted papilloma and papillary transitional cell carcinoma of the bladder: An evaluation by polymerase chain reaction. J Clin Pathol. 1997;50:1018-1021
24. Shigehara K, Sasagawa T, Doorbar J, et al. Etiological role of human papillomavirus infection for inverted papilloma of the bladder. J Med Virol. 2011;83:277-285
25. Blochin EB, Park KJ, Tickoo SK, et al. Urothelial carcinoma with prominent squamous differentiation in the setting of neurogenic bladder: Role of human papillomavirus infection. Mod Pathol. 2012;25:1534-1542
26. Husain E, Prowse DM, Ktori E, et al. Human papillomavirus is detected in transitional cell carcinoma arising in renal transplant recipients. Pathology. 2009;41:245-247
27. Yavuzer D, Karadayi N, Salepci T, et al. Role of human papillomavirus in the development of urothelial carcinoma. Med Oncol. 2011;28:919-923
28. Polesel J, Gheit T, Talamini R, et al. Urinary human polyomavirus and papillomavirus infection and bladder cancer risk. Br J Cancer. 2012;106:222-226
29. Panagiotakis GI, Papadogianni D, Chatziioannou MN, et al. Association of human herpes, papilloma and polyoma virus families with bladder cancer. Tumour Biol. 2012. [Epub ahead of print].
30. Alexander RE, Hu Y, Kim JB, et al. p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma. Mod Pathol. 2012;25:1526-1533
31. Guo CC, Gomez E, Tamboli P, et al. Squamous cell carcinoma of the urinary bladder: A clinicopathologic and immunohistochemical study of 16 cases. Hum Pathol. 2009;40:1448-1452
32. Westenend PJ, Stoop JA, Hendriks JG. Human papillomaviruses 6/11, 16/18 and 31/33/51 are not associated with squamous cell carcinoma of the urinary bladder. BJU Int. 2001;88:198-201
33. Cheng L, Leibovich BC, Cheville JC, et al. Squamous papilloma of the urinary tract is unrelated to condyloma acuminata. Cancer. 2000;88:1679-1686
34. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527
35. zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol. 1994;186:131-156
36. Benevolo M, Mottolese M, Marandino F, et al. Immunohistochemical expression of p16(INK4a) is predictive of HR-HPV infection in cervical low-grade lesions. Mod Pathol. 2006;19:384-391
37. Doxtader EE, Katzenstein AL. The relationship between p16 expression and high-risk human papillomavirus infection in squamous cell carcinomas from sites other than uterine cervix: A study of 137 cases. Hum Pathol. 2012;43:327-332
38. Keating JT, Cviko A, Riethdorf S, et al. Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol. 2001;25:884-891
39. Klaes R, Benner A, Friedrich T, et al. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol. 2002;26:1389-1399
40. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001;92:276-284
41. Pientong C, Ekalaksananan T, Kongyingyoes B, et al. Immunocytochemical staining of p16INK4a protein from conventional Pap test and its association with human papillomavirus infection. Diagn Cytopathol. 2004;31:235-242
42. Bishop JA, Ogawa T, Chang X, et al. HPV analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. Am J Surg Pathol. 2012;36:142-148
43. del Pino M, Bleeker MC, Quint WG, et al. Comprehensive analysis of human papillomavirus prevalence and the potential role of lowrisk types in verrucous carcinoma. Mod Pathol. 2012;25:1354-1363
44. Jordan RC, Lingen MW, Perez-Ordonez B, et al. Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol. 2012;36:945-954
45. Lewis JS Jr, Chernock RD, Ma XJ, et al. Partial p16 staining in oropharyngeal squamous cell carcinoma: Extent and pattern correlate with human papillomavirus RNA status. Mod Pathol. 2012;25:1212-1220
46. Schlecht NF, Brandwein-Gensler M, Nuovo GJ, et al. A comparison of clinically utilized human papillomavirus detection methods in head and neck cancer. Mod Pathol. 2011;24:1295-1305
47. Ukpo OC, Flanagan JJ, Ma XJ, et al. High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am J Surg Pathol. 2011;35:1343-1350
48. Samarawardana P, Dehn DL, Singh M, et al. p16(INK4a) is superior to high-risk human papillomavirus testing in cervical cytology for the prediction of underlying high-grade dysplasia. Cancer Cytopathol. 2010;118:146-156
49. Darragh TM, Colgan TJ, Cox JT, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012;136:1266-1297
50. Hasegawa M, Deng Z, Maeda H, et al. Human papillomavirus load and physical status in sinonasal inverted papilloma and squamous cell carcinoma. Rhinology. 2012;50:87-94
51. Katori H, Nozawa A, Tsukuda M. Markers of malignant transformation of sinonasal inverted papilloma. Eur J Surg Oncol. 2005;31:905-911
52. Jenko K, Kocjan B, Zidar N, et al. In inverted papillomas HPV more likely represents incidental colonization than an etiological factor. Virchows Arch. 2011;459:529-538
53. Syrjanen K, Syrjanen S. Detection of human papillomavirus in sinonasal papillomas: Systematic review and meta-analysis. Laryngoscope. 2013;123:181-192
54. Sham CL, To KF, Chan PK, et al. Prevalence of human papillomavirus, Epstein-Barr virus, p21, and p53 expression in sinonasal inverted papilloma, nasal polyp, and hypertrophied turbinate in Hong Kong patients. Head Neck. 2012;34:520-533
55. Shah AA, Evans MF, Adamson CS, et al. HPV DNA is associated with a subset of Schneiderian papillomas but does not correlate with p16(INK4a) immunoreactivity. Head Neck Pathol. 2010;4:106-112
56. Hennell C, Jamison J, Wells M, et al. Inverted papilloma of the cervix and vagina: Report of 2 cases of a rare lesion associated with human papillomavirus 42. Hum Pathol. 2012;43:435-439
57. Sauter A, Matharu R, Hormann K, et al. Current advances in the basic research and clinical management of sinonasal inverted papilloma (review). Oncol Rep. 2007;17:495-504